GGrantIndex
← Search

PATHOLOGY

$78,870U10FY2002CANIH

Mayo Clinic Coll Of Medicine, Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Paper 39055377Paper 37539667Paper 36050448Paper 35859079Paper 34804634Paper 33154022Paper 32923882Paper 32504284Paper 31802506Paper 31213748Paper 30775161Paper 29848457Paper 29649081Paper 29530935Paper 29313954Paper 29164377Paper 29138761Paper 29044496Paper 28939223Paper 28921241Paper 28917648Paper 28786105Paper 28700816Paper 28691116Paper 28691057Paper 28687377Paper 28649983Paper 28646344Paper 28620884Paper 28533226Paper 28493308Paper 28402581Paper 28384065Paper 28375706Paper 28323331Paper 28280603Paper 28262692Paper 28239505Paper 28089762Paper 28006055Paper 27943153Paper 27881709Paper 27590208Paper 27534963Paper 27478689Paper 27468630Paper 27458945Paper 27374464Paper 27365012Paper 27302508Paper 27197192Paper 27098150Paper 27075674Paper 27060850Trial NCT01648348Trial NCT01369849Trial NCT01086605Trial NCT00869401Trial NCT00826540Trial NCT00738881Trial NCT00731731Trial NCT00699491Trial NCT00684983Trial NCT00641706Trial NCT00528645Trial NCT00459862Trial NCT00398112Trial NCT00369655Trial NCT00329719Trial NCT00321724Trial NCT00316849Trial NCT00255762Trial NCT00238394Trial NCT00238303Trial NCT00110084Trial NCT00109967Trial NCT00098540Trial NCT00096434Trial NCT00096070Trial NCT00093756Trial NCT00079274Trial NCT00079235Trial NCT00052949Trial NCT00052689Trial NCT00049127Trial NCT00039494Trial NCT00033267Trial NCT00027612Trial NCT00026234Trial NCT00026182Trial NCT00016328Trial NCT00015990Trial NCT00015821Trial NCT00014170Trial NCT00006226Trial NCT00005970Trial NCT00005036Trial NCT00003869Trial NCT00003140Patent 8507518

Abstract

The primary functions of the NCCTG Pathology Committee are to: 1. Assure accurate histopathologic diagnosis for patients participating in NCCTG clinical trial through its quality assurance program. 2. Facilitate translational research by procuring, processing, and providing tissue specimens to the Research Base Tissue Resource for laboratory correlative science studies. 3. Participate in development and review of NCCTG clinical trials. 4. Conduct research on the prognostic significance of various parameters and collaborate on translational research studies with laboratory scientists at the Research Base. Over the past grant period, the Pathology Committee has reviewed tissue specimens from 2,887 patients on 26 protocols to assure correct diagnosis. In addition, 34 discrepancies in diagnosis were resolved at the semi-annual Group meetings, and 24 colorectal cancer and eight breast cancer cases were audited to assure correct diagnosis in these tumor types where mandatory review was not instituted. Members of the Pathology Committee have provided 7,175 tissue blocks to the Research Base Tissue Resource from patients participating in 47 NCCTG clinical trials in support of laboratory correlative studies of prognostic and predictive markers since 1994. Eight manuscripts have been published since 1996, reporting laboratory correlative studies in breast cancer, colorectal cancer, lung cancer, ovarian cancer, and brain tumors using NCCTG tissue blocks. Several other studies are in progress. Other, NCCTG pathologists were authors of co-authors of 14 published and three submitted manuscripts during the past grant period. Future plans are to continue our quality assurance program, with mandatory pathology reviews where it is warranted and selective audits where appropriate. We will maintain our excellent record of tissue block submission for laboratory correlative studies, and will develop systems to procure fresh tumor tissue for molecular studies where required. Finally, we will investigate pathologic prognostic factors of interest to the NCCTG community physicians and clinical investigators, and collaborate on molecular studies with members of the Translational Research Coordinating Committee.

View original record on NIH RePORTER →